...
首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria.
【24h】

Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria.

机译:在无微量白蛋白尿的2型糖尿病患者中,血浆脂肪酸结合蛋白4随着肾功能障碍而增加。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Fatty acid-binding protein 4 (FABP4) has been linked to metabolic syndrome development, diabetes, and arteriosclerosis, but the role of FABP4 in target organ damage has not been assessed. We evaluated whether plasma FABP4 is associated with renal dysfunction in type 2 diabetic patients. METHODS: In 263 individuals (161 type 2 diabetic patients and 102 healthy nondiabetic controls), we analyzed the correlation between FABP4 and creatinine or glomerular filtration index (MDRD-GFR) regarding the presence or absence of microalbuminuria. Patients with severe chronic kidney disease (MDRD-GFR <30 mL/min/1.73 m(2)) or albuminuria were not included. RESULTS: FABP4 concentrations were higher in diabetic patients with MDRD-GFR <60 mL/min/1.73 m(2) (P <0.001). We observed a significant, direct correlation between FABP4 and creatinine (r = 0.446, P <0.001) and an inverse correlation between FABP4 and MDRD-GFR (r = -0.511, P <0.001) in type 2 diabetic patients, but not in nondiabetic individuals. These correlations were sustained when only those patients without microalbuminuria were analyzed (r = 0.414, P <0.001 and r = -0.510, P <0.001, respectively). Type 2 diabetic patients with FABP4 in the highest tertile compared with those in the lower tertiles had increased adjusted odds ratios for moderate renal dysfunction [7.5 (95%CI 1.8-30.7), P = 0.005 and 15.3 (3.1-76.4), P = 0.001; respectively], independent of microalbuminuria. CONCLUSIONS: High FABP4 plasma concentrations are associated with high plasma creatinine and low MDRD-GFR in patients with type 2 diabetes even in the absence of microalbuminuria or clinically relevant alterations of creatinine and MDRD-GFR values. FABP4 concentrations should be taken into consideration as an early marker of kidney damage in patients with type 2 diabetes.
机译:背景:脂肪酸结合蛋白4(FABP4)与代谢综合征的发展,糖尿病和动脉硬化有关,但尚未评估FABP4在靶器官损伤中的作用。我们评估了血浆FABP4是否与2型糖尿病患者的肾功能不全相关。方法:在263名个体(161名2型糖尿病患者和102名健康非糖尿病对照组)中,我们分析了FABP4与肌酐或肾小球滤过指数(MDRD-GFR)之间是否存在微量白蛋白尿的相关性。严重慢性肾脏疾病(MDRD-GFR <30 mL / min / 1.73 m(2))或蛋白尿的患者不包括在内。结果:MDRD-GFR <60 mL / min / 1.73 m(2)的糖尿病患者中FABP4浓度较高(P <0.001)。我们观察到2型糖尿病患者中FABP4与肌酐之间存在显着的直接相关性(r = 0.446,P <0.001),而FABP4与MDRD-GFR之间呈负相关(r = -0.511,P <0.001),而非糖尿病患者则没有个人。当仅分析那些无微量白蛋白尿的患者时,这些相关性得以维持(分别为r = 0.414,P <0.001和r = -0.510,P <0.001)。三分位数最高的FABP4型糖尿病患者与三分位数较低的2型糖尿病患者中度肾功能不全的调整比值比增加[7.5(95%CI 1.8-30.7),P = 0.005和15.3(3.1-76.4),P = 0.001;分别独立于微量白蛋白尿。结论:即使没有微量蛋白尿或肌酐和MDRD-GFR值在临床上无相关变化,2型糖尿病患者的高FABP4血浆浓度与高血浆肌酐和低MDRD-GFR相关。应将FABP4浓度视为2型糖尿病患者肾脏损害的早期指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号